6714-29-0

Usage

Uses

Used in Medicinal Chemistry:
2,3-dihydro-1H-imidazo[1,2-b]pyrazole is used as a ligand for various biological targets due to its unique structural properties and reactivity. This allows it to be a key component in the development of pharmaceutical drugs and other organic compounds.
Used in Pharmaceutical Drug Development:
2,3-dihydro-1H-imidazo[1,2-b]pyrazole is used as a building block in the synthesis of pharmaceutical drugs. Its potential as a ligand for biological targets makes it a valuable component in creating new and effective medications.
Used in Organic Synthesis:
2,3-dihydro-1H-imidazo[1,2-b]pyrazole is used as a component in the synthesis of other organic compounds. Its reactivity and structural properties make it a suitable candidate for use in organic synthesis processes.

InChI:InChI=1/C5H7N3/c1-2-7-8-4-3-6-5(1)8/h1-2,6H,3-4H2

Upstream product

• 106-93-4 ethylene dibromide 
• 1225387-53-0 3⁽⁵⁾-aminopyrazole 
• 5346-53-2 5-amino-4-cyano-1-(2-hydroxyethyl)-pyrazole 

Relevant academic research and scientific papers

Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology

The tumor microenvironment contains high concentrations of TGFβ, a crucial immunosuppressive cytokine. TGFβ stimulates immune escape by promoting peripheral immune tolerance to avoid tumoricidal attack. Small-molecule inhibitors of TGFβR1 are a prospective method for next-generation immunotherapies. In the present study, we identified selective 4-aminoquinoline-based inhibitors of TGFβR1 through structural and rational-based design strategies. This led to the identification of compound 4i, which was found to be selective for TGFβR1 with the exception of MAP4K4 in the kinase profiling assay. The compound was then further optimized to remove MAP4K4 activity, since MAP4K4 is vital for proper T-cell function and its inhibition could exacerbate tumor immunosuppression. Optimization efforts led to compound 4s that inhibited TGFβR1 at an IC50 of 0.79 ± 0.19 nM with 2000-fold selectivity against MAP4K4. Compound 4s represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology.

TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.

Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists

Corticotropin releasing factor (CRF) antagonists of Formulae (I) or (II): and their use in treating psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.